Moderna and Merck advance personalized mRNA melanoma vaccine development

Moderna and Merck have demonstrated clinical success with a personalized mRNA vaccine targeting melanoma recurrence. This milestone validates the platform's efficacy and is expected to accelerate competitive R&D efforts across the pharmaceutical sector for broader oncology applications.